ALACHUA, Fla. and TAMPA, Fla. — December 4, 2025 — Leads & Copy —
Axogen, Inc. (NASDAQ: AXGN) announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for AVANCE® (acellular nerve allograft-arwx). AVANCE is an acellular nerve scaffold designed to treat adult and pediatric patients aged 1 month or older who have sensory, mixed, and motor peripheral nerve discontinuities.
The FDA approved the indications for sensory nerve discontinuities >25mm and for mixed and motor nerve discontinuities under its Accelerated Approval pathway. This decision was based on the effect on static two-point discrimination in sensory nerve gaps ≤25mm, which provided empirical evidence to reasonably predict clinical benefit. However, continued approval for these indications depends on verification and description of clinical benefit in confirmatory studies.
Michael Dale, Axogen’s Chief Executive Officer, expressed pride in the approval, noting that it represents a significant shift from the product’s previous classification as a human tissue product, aligning it with the FDA’s classification of AVANCE as a biologic. He stated that this milestone clarifies and strengthens Axogen’s regulatory footing and confirms AVANCE as an acceptable therapeutic option for treating peripheral nerve discontinuities in all of Axogen’s present nerve repair use cases.
The approval and transition to a biologic regulatory framework are expected to reassure stakeholders that AVANCE has undergone rigorous evaluation and is safe, pure, and potent for its intended use, with benefits outweighing known or potential risks. Dale thanked the FDA and the surgical community for their collaboration in making this therapy available to patients.
Commercial availability of the licensed AVANCE product is expected early in the second quarter of 2026. In the meantime, AVANCE remains available under the current tissue framework.
Indications:
AVANCE® is indicated for the treatment of adult and pediatric patients aged one month and older with:
- Sensory nerve discontinuity (≤25mm)
- Sensory nerve discontinuity (>25mm); Approved under accelerated approval based on static two-point discrimination (s2PD) at 12 months in sensory nerve gaps ≤25 mm, which reasonably predicts clinical benefit. Continued approval is contingent upon confirmatory clinical trial results.
- Mixed and motor nerve discontinuity; Approved under accelerated approval based on s2PD outcomes in sensory nerves; continued approval is contingent upon confirmatory clinical trial results.
Important Safety Information:
Warnings and Precautions:
- Procedural Complications: Monitor for procedural complications, including pain, hyperesthesia, infection, implant site swelling, adhesions, hypertrophic scar formation, impaired motor or sensory function, bleeding, and neuroma formation, and manage accordingly.
- Transmission of Infectious Diseases: Because AVANCE is made from human donor tissue, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
Adverse Reactions:
- The most common adverse reactions (≥2%) were procedural pain (4%) and hyperesthesia (3%).
For complete warnings, precautions, and risk information, see the full prescribing information available at www.avancenervegraft.com or by calling 1-888-296-4631.
Axogen (NASDAQ: AXGN) focuses on the science, development, and commercialization of technologies for peripheral nerve repair. The company’s mission is to make nerve repair the expected standard of care through research, education, and collaboration with surgeons and healthcare providers.
Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™. These products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
For more information, visit www.axogeninc.com.
Axogen, Inc.
InvestorRelations@axogeninc.com
Source: Axogen, Inc.
